Published in Hum Vaccin Immunother on January 01, 2015
Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing. Int J Mol Sci (2016) 0.79
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol (1977) 5.21
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol (2014) 3.81
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine (2010) 1.94
PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecol Oncol (2008) 1.67
Human papillomavirus vaccines--immune responses. Vaccine (2012) 1.40
Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis (2011) 1.36
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
Urine testing for HPV: rationale for using first void. BMJ (2014) 1.17
Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol (2011) 1.01
Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol (2013) 1.00
The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines (2014) 0.91
Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis (2014) 0.91
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
The global impact of vaccination against hepatitis B: a historical overview. Vaccine (2008) 2.84
Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med (2004) 2.44
Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol (2009) 2.21
Hepatitis A and E: update on prevention and epidemiology. Vaccine (2009) 2.00
Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium. BMC Infect Dis (2009) 1.99
Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics (2003) 1.85
AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis (2010) 1.80
Hepatitis B and the need for a booster dose. Clin Infect Dis (2011) 1.80
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. Math Biosci (2009) 1.58
Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine (2009) 1.55
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol (2009) 1.49
Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS One (2010) 1.37
Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis (2007) 1.36
Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J Travel Med (2003) 1.36
Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis (2007) 1.27
Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros (2005) 1.25
Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine (2008) 1.24
The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis (2011) 1.24
Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam Pract (2010) 1.24
Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. PLoS One (2013) 1.17
Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J (2011) 1.16
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine (2009) 1.16
Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine (2006) 1.13
Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine (2012) 1.11
Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine (2012) 1.10
Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine (2012) 1.10
Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium. Med Decis Making (2008) 1.08
Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J (2011) 1.06
Current issues in adolescent immunization. Vaccine (2008) 1.06
Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006). Vaccine (2006) 1.06
Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol (2011) 1.05
The health and economic burden of rotavirus disease in Belgium. Eur J Pediatr (2008) 1.05
Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics (2008) 1.04
Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin (2011) 1.03
Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine (2007) 1.03
Hepatitis B vaccination: how to reach risk groups. Vaccine (2002) 1.02
Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine (2011) 1.01
Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis (2003) 1.01
Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine (2010) 1.01
Vaccination coverage and sociodemographic determinants of measles-mumps-rubella vaccination in three different age groups. Eur J Pediatr (2008) 1.00
How to optimise the coverage rate of infant and adult immunisations in Europe. BMC Med (2007) 0.98
Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveill (2016) 0.98
European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr (2008) 0.96
Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine (2006) 0.96
Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. Vaccine (2009) 0.96
Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother (2012) 0.95
An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J (2010) 0.94
Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine (2006) 0.93
Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium). Vaccine (2011) 0.93
Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunol (2011) 0.93
Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines (2002) 0.93
Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-time PCR in flanders. Gynecol Obstet Invest (2010) 0.92
Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections. Acta Trop (2004) 0.91
Hepatitis B immunisation in Britain: time to change? BMJ (2006) 0.91
Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians. Clin Vaccine Immunol (2014) 0.90
Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol (2004) 0.90
A global prescription for adult immunization: time is catching up with us. Vaccine (2010) 0.89
Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J (2008) 0.89
Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J (2005) 0.89
European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr (2008) 0.89
Oral fluid as a medium for the detection of hepatitis B surface antigen. J Med Virol (2005) 0.89
Should Europe have a universal hepatitis B vaccination programme? BMJ (2013) 0.88
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine (2009) 0.88
Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model. BMC Public Health (2011) 0.88
European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. Pediatr Infect Dis J (2015) 0.87
Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine (2003) 0.86
Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol (2002) 0.86
Prevention and control of viral hepatitis through adolescent health programmes in Europe. Vaccine (2007) 0.86
Rotavirus. J Pediatr Gastroenterol Nutr (2008) 0.86
The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: review and consensus statement on hepatitis A and B vaccination. J Travel Med (2007) 0.86
Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. Acta Paediatr (2009) 0.86
An economic evaluation of varicella vaccination in Italian adolescents. Vaccine (2004) 0.85
The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. J Immunol Methods (2010) 0.85
Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination. J Infect Dis (2009) 0.84
Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines (2005) 0.84
Effect of hepatitis A vaccination programs. JAMA (2005) 0.83
Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines (2003) 0.83
Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine (2011) 0.83
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial. Vaccine (2011) 0.82
Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery. Curr Opin Infect Dis (2012) 0.82
Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysis. PLoS One (2009) 0.82
Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin (2007) 0.81
Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J (2009) 0.81
Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine (2002) 0.81
Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr Infect Dis J (2007) 0.81
Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travelers. J Travel Med (2004) 0.80
Immune memory and immune response in children from Bulgaria 5-15 years after primary hepatitis B vaccination. Pediatr Infect Dis J (2013) 0.80
Caregivers' willingness to pay to reduce the number of vaccine injections in infants. Pediatr Infect Dis J (2009) 0.80
Zoster in monasteries: some clarification needed. Clin Infect Dis (2012) 0.80
The prevalence of the human papillomavirus in cervix and vagina in low-risk and high-risk populations. Scand J Infect Dis (2004) 0.80